Itraconazole treatment of murine aspergillosis
- 1 January 1985
- journal article
- research article
- Published by Oxford University Press (OUP) in Medical Mycology
- Vol. 23 (3) , 219-223
- https://doi.org/10.1080/00362178585380321
Abstract
ICR mice were challenged with conidia of Aspergillus fumigatus given either intranasally or intravenously, and treated beginning 1 day later with itraconazole, amphotericin B, or the vehicles for these two agents. Mice challenged intravenously and treated with either antifungal drug had prolonged survival over controls, and had lower tissue counts in the kidneys than the controls. However, mice challenged intranasally had neither prolonged survival nor lower lung tissue counts than the controls.This publication has 10 references indexed in Scilit:
- Itraconazole, a new triazole that is orally active in aspergillosisAntimicrobial Agents and Chemotherapy, 1984
- In vitro studies with R 51,211 (itraconazole)Antimicrobial Agents and Chemotherapy, 1984
- Antimycotic azoles. 7. Synthesis and antifungal properties of a series of novel triazol-3-onesJournal of Medicinal Chemistry, 1984
- R 51211 (itraconazole) therapy of murine cryptococcosisMedical Mycology, 1984
- Treatment of Experimental Murine Aspergillosis with BAY n7133The Journal of Infectious Diseases, 1983
- Combination Therapy of Experimental Histoplasmosis and Cryptococcosis with Amphotericin Band KetoconazoleClinical Infectious Diseases, 1980
- Suppression of Cryptococcosis and Histoplasmosis by Ketoconazole in Athymic Nude MiceThe Journal of Infectious Diseases, 1980
- Aspergillus pneumonia in hematologic malignancy. Improvements in diagnosis and therapyArchives of internal medicine (1960), 1977
- Aspergillosis complicating neoplastic diseaseThe American Journal of Medicine, 1973